Free Fastin Weight Loss Pills Offered by

WEST NEW YORK, N.J., April 14 /PRNewswire/ -- Fastin, from Hi-Tech Pharmaceuticals, is by far the hottest-selling nutriceutical weight loss supplement on the market today. The folks at are so confident in the results achieved from a recent customer satisfaction survey that they are now offering a free trial on their web site

The rights to Fastin were previously owned by Smith Kline Beecham Pharmaceuticals, and most recently acquired Hi-Tech Pharmaceuticals. Smith Kline Beecham developed phentermine HCL under the brand name Fastin up until 1998.

Fastin, from Hi-Tech, is a pharmaceutical-grade dietary supplement indicated for weight loss in extremely overweight individuals. Fastin has both immediate and delayed release profiles for appetite suppression, energy, and weight loss. Fastin's patent-pending formula contains B-methyl-phenethylamine, 37.5mg, and was developed with the help of Mark Wright, M.D., a bariatric physician.

Fastin is available only from a select group of retailers, but is the only site offering a free trial of the product. Frank Huerta, spokesperson for sales and marketing, released a statement saying, "We are pleased to offer Fastin to consumers on this trial basis and we're supremely confident that customers will continue to order the product because of the effectiveness. We've never offered something for free, but the folks at Hi-Tech have made a product that actually does what it's supposed to and we're excited to be working with them on this offer."

For additional information about the free Fastin promotion, call 1-877-807-2007 or visit

This release was issued through eReleases(TM). For more information, visit


Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.